Cognitive Function in a Randomized Trial of Evolocumab

Overview of attention for article published in New England Journal of Medicine, August 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

news: 11 news outlets
blogs: 4 blogs
twitter: 86 X users
facebook: 2 Facebook pages
googleplus: 2 Google+ users

reddit: 5 Redditors
video: 2 YouTube creators
guideline: 9 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 342 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 91 X posts from 86 X users, with an upper bound of 1,542,394 followers.

@josemacatalina Aquí dicen justo lo contrario. Personas tratadas durante años con estatinas + fármacos que llevan el LDL incluso hacia 20–40 mg/dL no han mostrado una señal consistente de deterioro cognitivo. https://t.co/s1oKPebuMV

@lipo_fan https://t.co/PD7PyKsDAG

@Brinkswealth10 @Drlipid https://t.co/eWBSxwAfqu

@LeoAugCarbonera @rgiugliano @DrM_ODonoghue We used the CANTAB spatial working memory strategy index of executive function, consistent with the parent EBBINGHAUS trial: https://t.co/22i0cossQi Curious to hear your thoughts as a neurologist :)

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 87 additional X posts.